DK3126521T3 - HNF4G-RSPO2-fusionsgen - Google Patents

HNF4G-RSPO2-fusionsgen Download PDF

Info

Publication number
DK3126521T3
DK3126521T3 DK15772589.6T DK15772589T DK3126521T3 DK 3126521 T3 DK3126521 T3 DK 3126521T3 DK 15772589 T DK15772589 T DK 15772589T DK 3126521 T3 DK3126521 T3 DK 3126521T3
Authority
DK
Denmark
Prior art keywords
hnf4g
rspo2 fusion
rspo2
fusion
Prior art date
Application number
DK15772589.6T
Other languages
English (en)
Inventor
Jie Cai
Henry Li
Original Assignee
Crown Bioscience Inc Taicang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Bioscience Inc Taicang filed Critical Crown Bioscience Inc Taicang
Application granted granted Critical
Publication of DK3126521T3 publication Critical patent/DK3126521T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK15772589.6T 2014-04-04 2015-04-03 HNF4G-RSPO2-fusionsgen DK3126521T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410135569 2014-04-04
PCT/CN2015/075882 WO2015149720A1 (en) 2014-04-04 2015-04-03 Hnf4g-rspo2 fusion gene and use thereof in treatment of cancer

Publications (1)

Publication Number Publication Date
DK3126521T3 true DK3126521T3 (da) 2019-06-17

Family

ID=54239415

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15772589.6T DK3126521T3 (da) 2014-04-04 2015-04-03 HNF4G-RSPO2-fusionsgen
DK15773840.2T DK3126528T3 (da) 2014-04-04 2015-04-03 Fremgangsmåder til bestemmelse af modtagelighed over for MEK/ERK-inhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15773840.2T DK3126528T3 (da) 2014-04-04 2015-04-03 Fremgangsmåder til bestemmelse af modtagelighed over for MEK/ERK-inhibitorer

Country Status (7)

Country Link
US (3) US10501805B2 (da)
EP (3) EP4012049A3 (da)
CN (3) CN106460060B (da)
DK (2) DK3126521T3 (da)
ES (2) ES2727374T3 (da)
PT (2) PT3126528T (da)
WO (2) WO2015149721A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102413458B1 (ko) * 2016-08-04 2022-06-24 시즈오카켄 암의 발증 리스크의 유무를 판정하는 방법
WO2018058490A1 (zh) * 2016-09-30 2018-04-05 武汉华大吉诺因生物科技有限公司 Col14a1衍生的肿瘤抗原多肽及其应用
WO2020140927A1 (en) * 2019-01-02 2020-07-09 Crownmab Biotech Inc. Cancer treatment using multi-targeted kinase inhibitor in combination of protein kinase biomarkers
CN111434353A (zh) * 2019-02-02 2020-07-21 中国科学院上海营养与健康研究所 Ras抑制剂筛选及疗效标志物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
EP0390323B2 (en) 1989-03-29 2012-08-08 Johns Hopkins University Detection of loss of the wild-type p53 gene
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
EP0857210B1 (en) 1995-10-23 2003-09-03 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6045997A (en) 1995-11-23 2000-04-04 Duke University Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
AR007855A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
SK6652000A3 (en) 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
KR100743287B1 (ko) 1998-05-29 2007-07-26 수젠, 인크. 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
AU2007282535B9 (en) 2006-08-08 2013-06-20 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as PI3K inhibitor and use thereof
EP2074226A2 (en) * 2006-09-19 2009-07-01 Novartis AG Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
CL2009000241A1 (es) 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
CN101524529B (zh) * 2008-03-04 2011-09-28 中国人民解放军第二军医大学 HNF4α诱导分化治疗人体恶性实体瘤
CN102439174B (zh) 2009-02-19 2015-02-04 康奈尔大学 基于检测slc45a3-elk4融合转录子的用于诊断前列腺癌的组合物和方法
US9067986B2 (en) * 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US8945556B2 (en) * 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
CN104689318A (zh) * 2010-11-19 2015-06-10 葛兰素史密斯克莱知识产权（第2号）有限公司 使用braf抑制剂的治疗方法
EP2670866A4 (en) 2011-04-05 2015-09-02 Translational Genomics Res Inst BIOMARKERS AND METHOD OF APPLICATION THEREFOR
CN103571848B (zh) * 2012-08-10 2016-06-29 安徽医科大学第一附属医院 点状掌跖角化病的致病基因及其用途

Also Published As

Publication number Publication date
WO2015149720A1 (en) 2015-10-08
CN111808957A (zh) 2020-10-23
EP4012049A3 (en) 2022-08-24
PT3126521T (pt) 2019-06-27
DK3126528T3 (da) 2021-11-08
EP3126528A4 (en) 2018-02-21
US20180282814A1 (en) 2018-10-04
CN106460060A (zh) 2017-02-22
WO2015149721A1 (en) 2015-10-08
CN106536753A (zh) 2017-03-22
ES2896404T3 (es) 2022-02-24
EP4012049A2 (en) 2022-06-15
EP3126521B1 (en) 2019-03-20
PT3126528T (pt) 2021-09-09
EP3126521A1 (en) 2017-02-08
US10683550B2 (en) 2020-06-16
CN106536753B (zh) 2020-07-21
EP3126528A1 (en) 2017-02-08
US10501805B2 (en) 2019-12-10
EP3126521A4 (en) 2017-11-08
ES2727374T3 (es) 2019-10-15
CN106460060B (zh) 2020-02-11
EP3126528B1 (en) 2021-08-18
US20200123622A1 (en) 2020-04-23
US20170114414A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
FIC20240044I1 (fi) Odronekstamabi
FIC20230037I1 (fi) Glofitamabi
FIC20240035I1 (fi) Toferseeni
FIC20240015I1 (fi) Zilbrysq - tsilukoplaani
FIC20220017I1 (fi) Lonapegsomatropiini
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3006072T3 (da) Karadgang
DK3107562T3 (da) P97-ids-fusionsproteiner
FIC20240047I1 (fi) Frukintinibi
FIC20230016I1 (fi) Nirsevimabi
EP4011484C0 (en) CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS
DK4242916T3 (da) Forstøver
DK3183340T3 (da) Termolabile exonukleaser
DE112015001664A5 (de) Betätigungsaktuator
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DE112015005041A5 (de) Gargerätevorrichtung
DK3110439T3 (da) Pcsk9-vacciner
DE102014000623A8 (de) Halbhohlnietelement
DK3009858T3 (da) Skyradar
FI20145913A (fi) Staattorimekanismi
DE112015001633A5 (de) Betätigungsaktuator
DK3447493T3 (da) Proteinrettede ortologer